<DOC>
	<DOCNO>NCT01538771</DOCNO>
	<brief_summary>Prospective , randomized open label trial Hypothesis - Infusion intracoronary darbepoetin-alpha time reperfusion may reduce infarct size post-infarct pathologic leave ventricular remodel patient ST-segment elevation myocardial infarction . Methods - Randomization control group treatment group - Treatment group : Darbepoetin-alpha 300ug intracoronary bolus infusion via over-the-wire balloon system simultaneously first balloon inflation conventional treatment - Control group : conventional treatment Endpoints - peak CK-MB &amp; troponin level : baseline,6h,12hr,18hr , 24hr , 36hr 48hr - MRI baseline : infarct size , area risk salvage myocardium - MRI 4 month : prevalence pathologic leave ventricle remodeling ( definition : increase end-diastolic volume index &gt; 20 % compare baseline ) - safety endpoint : cardiac death , nonfatal myocardial infarction , stent thrombosis , ischemic stroke , hospital readmission heart failure ischemic symptom , bleed urgent target lesion revascularization</brief_summary>
	<brief_title>Intracoronary Darbepoetin-alpha Reduce The Infarct Size Post-Infarct Remodeling</brief_title>
	<detailed_description>[ Eligibility Criteria ] 1 . Patients , regardless gender , age 18 80 year eligible within 12 hour onset ST-segment myocardial infarction decide treat primary percutaneous coronary intervention . [ Exclusion criterion ] 1 . Uncontrolled congestive heart failure ( Killip class II III , cardiogenic shock ) 2 . History malignancy 3 . Serious hematological disease 4 . Current infectious disease require antibiotic therapy 5 . Baseline creatinine level &gt; 2.0 mg/dL dependence dialysis 6 . Known hypersensitivity contraindication heparin , aspirin , clopidogrel , sirolimus , everolimus , contrast medium darbepoetin-α [ Primary endpoint ] Myocardial infarct size , estimate measurement peak level cardiac biomarker ( CK-MB troponin-I patient follow 48 hour every 6 hour ) [ Secondary end point ] 1 . The infarct size , measure area delay enhancement see cardiac magnetic resonance ( CMR ) image average four day ST-segment elevation myocardial infarction ( baseline ) 2 . The proportion area risk ( AAR ) salvage myocardium , calculate formula ; [ AAR - Infarct size ] / AAR X 100 ( % ) 3 . The change leave ventricular ejection fraction ( LVEF ) , LV end-diastolic volume ( LVEDV ) , LV end-systolic volume ( LVESV ) assess CMR four day four month 4 . LV remodel index [ ( LVEDV four month - baseline LVEDV ) / baseline LVEDV X 100 % ] incidence pathologic LV remodeling ( LV remodel index &gt; 20 % ) ; [ Safety endpoint ] The incidence composites cardiovascular endpoint ( cardiac death , nonfatal myocardial infarction , stent thrombosis , ischemic stroke , hospital readmission heart failure ischemic symptom , bleed urgent target lesion revascularization ) assess four month .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients STelevation myocardial infarction ( MI ) within 12 hour onset Suitable coronary anatomy PCI Age &lt; 80 yr Uncontrolled congestive heart failure ( Killip class II III , cardiogenic shock ) History malignancy Serious hematological disease Current infectious disease require antibiotic therapy Baseline creatinine level &gt; 2.0 mg/dL dependence dialysis Known hypersensitivity contraindication heparin , aspirin , clopidogrel , sirolimus , everolimus , contrast medium darbepoetinα</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Myocardial reperfusion injury</keyword>
</DOC>